Drug Induced Liver Injury
Note: this meeting was held March 20-21, 2013
Detecting and Evaluating Drug-Induced Liver Injury and Dysfunction
What’s Normal? What’s Not? What Should We Do About It?
DILI remains a major problem for drug development, and a clinical concern after marketing. We need new understanding, better communication, to avoid the problems. This academic-industry-government international conference will discuss new findings and thinking about drug-induced liver injury (DILI) and dysfunction (DILD), with presentations by experts in clinical hepatology and other fields, and active discussion with all registrants. Come and participate in this conference.
Co-sponsored by FDA/CDER, C-Path, and PhRMA
Endorsed by NIH DILIN and AASLD
John R. Senior, MD and Lana Pauls, MPH
Mark Avigan, MD, CM; Michael Merz, MD; Arie Regev, MD; Leonard Seeff, MD and Paul Watkins, MD
Presentations (Note: Click on the Presentation Title to view slides)